A
Avere Therapeutics
Once-weekly oral therapy for IL-23 inflammatory diseases.
About Avere Therapeutics
Avere Therapeutics is a biotechnology company developing oral therapies for the treatment of IL-23-driven inflammatory diseases. Avere's lead asset, AVR-001, is an oral peptide IL-23 receptor antagonist engineered for once-weekly dosing, with the potential to deliver competitive efficacy in a convenient oral form. Avere is initially advancing AVR-001 in psoriasis, with potential to expand into ulcerative colitis, Crohn's disease, and psoriatic arthritis. The company holds ex-Greater China rights to AVR-001 under a license from Hansoh.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Autoimmune, Inflammatory Diseases
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2026 | $500M | $2B | General Atlantic · RTW Investments · Janus Henderson Investors · Venrock Healthcare Capital Partners | ↗ |
| IPO✓Exit | Jul 2026 | $0 | — | Undisclosed | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Avimer BioAI-optimized protein nanoparticles restoring immune balance. |
United States | Operational | 3 | — | — |
 QRETIX-AIAI-powered platform for accelerated drug discovery. |
— | Operational | |||
 Knoubis BioPhosphatase-targeting biologics for autoimmune disease treatment. |
San Diego, United States | Operational | |||
 I Derm PharmaFirst-in-class oral therapy for moderate-to-severe psoriasis. |
— | Operational | |||
 Bodi HekangTreg-based therapies for autoimmune and inflammatory disorders. |
Shaoxing, China | Operational | |||
 Navigator MedicalBispecific antibody therapies for complex autoimmune diseases. |
Memphis, United States | Operational | |||
 palsideSpecializing in solutions for inflammatory and fibrotic diseases. |
— | Operational | |||
 Beeline MedicinesPrecision therapies for autoimmune and inflammatory diseases. |
Stamford, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later9 investors entered at this stage
General Atlantic
RTW Investments
Janus Henderson Investors- VPVenrock Healthcare Capital Partners
Sirenia Capital Management
Wellington Management
BB Biotech
ADAR1 Capital Management
Eventide Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avere Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avere Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.